The authors investigated carboplatin with nab-paclitaxel on every-3-week and weekly schedules. Carboplatin and nab-paclitaxel demonstrated activity in ES-SCLC but required frequent dose adjustments.

READ FULL ARTICLE Curated publisher From Mdlinx